ABI3BP and prostate adenocarcinoma: As a result of the study, lower expression of ABI3BP was observed in the following tumor types: Bladder Urothelial Carcinoma, Breast Invasive Carcinoma, Colon Adenocarcinoma, Esophageal Carcinoma, Head and Neck Squamous Cell Carcinoma, Kidney Chromophobe, Liver hepatocellular carcinoma, Lung adenocarcinoma, Lung squamous cell carcinoma, Prostate adenocarcinoma, Rectum adenocarcinoma, Stomach adenocarcinoma, Thyroid carcinoma, Uterine Corpus Endometrial Carcinomax.